Thursday, October 23, 2014 10:13:00 PM
"The implications to the results of the trial are broad reaching and create a tremendous opportunity for our infectious disease division"
This trial confirms the potential of Defensin mimetics. Brilacidin is just the tip of the iceberg.
It is a revolutionary drug: new family of pharmaceuticals, no resistance , single dose efficacy, no serious side effects. Plus we hold the patents to Brilacidin and its analogues.
How many potential drugs can be developed in this new family of drugs? CTIX has reported it is studying defensin mimetics for fungal infections, tuberculosis, malaria. Studies will be performed for every infection known including: viruses, parasites, protozoa, prions.
If there is no resistance then there will be no objections to developing the huge veternarian and ag market
Plus CTIX has hinted at its noninflammatory properties.
FDA expediated review should be expected.
Major Pharma partners should be lining up.
all IMO Farrell
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM